Core Insights - ADC Therapeutics is advancing its clinical programs for ZYNLONTA, with updated data from LOTIS-7 expected by the end of 2025 and topline results from LOTIS-5 anticipated in the first half of 2026 [1][5][2] Financial Results - For Q3 2025, net product revenues were $15.8 million, a decrease from $18.0 million in Q3 2024. Year-to-date revenues were $51.2 million compared to $52.9 million for the same period in 2024 [4][19] - Research and Development (R&D) expenses for Q3 2025 were $26.8 million, down from $32.5 million in Q3 2024. Year-to-date R&D expenses increased to $85.8 million from $82.5 million in 2024 [4][19] - Selling and Marketing (S&M) expenses remained stable at $10.7 million for Q3 2025, with a slight decrease in year-to-date expenses to $31.4 million from $32.8 million in 2024 [4][19] - General and Administrative (G&A) expenses decreased to $8.3 million for Q3 2025 from $10.0 million in Q3 2024, and year-to-date G&A expenses were $27.1 million compared to $32.3 million in 2024 [4][19] - The net loss for Q3 2025 was $41.0 million, or $0.30 per share, an improvement from a net loss of $44.0 million, or $0.42 per share, in Q3 2024. Year-to-date net loss was $136.2 million, compared to $127.1 million in 2024 [4][19] Operational Updates - The company completed a $60 million PIPE financing, with net proceeds of approximately $57.6 million expected to fund the commercial expansion of ZYNLONTA [2][5] - Updated data from the Phase 2 investigator-initiated trial of ZYNLONTA in r/r follicular lymphoma showed an overall response rate of 98.2% and a complete response rate of 83.6% [5][4] - IND-enabling activities for a PSMA-targeting ADC are ongoing, with completion expected by the end of 2025 [5][4] Future Outlook - Multiple clinical catalysts are anticipated across LOTIS-7, LOTIS-5, and ongoing Phase 2 IITs, with the first data readout expected before the end of 2025 [2][5] - The company plans to engage with the FDA once sufficient data from LOTIS-7 is available, with potential regulatory submissions and approvals expected in 2027 [5][4]

Core Insights - Defence Therapeutics Inc. successfully presented new data on its proprietary Accum® platform at the 16th World ADC Conference in San Diego, generating significant interest from the scientific and industry communities [2][3]. Company Developments - The presentation highlighted how Accum® enhances intracellular delivery and payload release, improving the potency and therapeutic index of antibody-drug conjugates (ADCs) [3]. - The company plans to expand testing of Accum® across a wider range of commercial and clinical-stage ADCs to validate its potential in enhancing efficacy and patient outcomes [4]. - Defence Therapeutics aims to demonstrate that Accum® can universally enhance ADC performance, regardless of the payload or antibody used, and is engaging with industry partners to accelerate evaluations [5]. Technology Overview - The Accum® technology is designed for precision delivery of ADCs in their intact form to target cells, which can lead to increased efficacy and potency against cancer [6].

Industry Overview - The Zacks REIT and Equity Trust - Retail industry is showing resilience as landlords adapt and reposition assets for long-term stability, focusing on necessity-based and experience-driven retailers [1][3] - The industry is experiencing a rebound driven by renewed consumer interest in in-store shopping, despite past challenges such as declining foot traffic and store closures [2] Key Drivers - Strategic re-tenanting and disciplined expansion are strengthening occupancy and cash flows, with limited new supply helping to preserve rent levels and investor confidence [1][4] - The lack of new construction activity has minimized competitive pressure on existing assets, allowing occupancy and rents to hold firm [4] Consumer Behavior - The outlook for retail REITs is closely linked to consumer behavior, with economic softness and rising costs making households more selective in their spending [5] - Wealthier consumers continue to support high-end demand, while middle-income shoppers are cutting back, leading to an uneven spending landscape [5] Industry Performance - The Zacks REIT and Equity Trust - Retail industry carries a Zacks Industry Rank 55, placing it in the top 23% of 243 Zacks industries, indicating robust near-term prospects [6][7] - The industry has underperformed the broader Zacks Finance sector and the S&P 500 over the past year, declining 5.6% compared to the S&P 500's rise of 22.3% [10] Valuation Metrics - The industry is currently trading at a forward 12-month price-to-FFO of 14.98X, below the S&P 500's forward P/E of 23.77X and the Finance sector's forward P/E of 16.94X [12] - Over the last five years, the industry has traded as high as 18.89X and as low as 12.21X, with a median of 15.22X [15] Company Highlights - **Agree Realty Corporation (ADC)**: Specializes in retail net-lease properties with a portfolio of approximately 2,603 properties totaling around 53.7 million square feet. The company raised its full-year 2025 investment guidance to $1.50 billion-$1.65 billion, indicating confidence in its capital deployment strategy [16][17] - **Federal Realty Investment Trust (FRT)**: Focuses on high-quality retail properties in affluent markets, with a recent acquisition of Annapolis Town Center enhancing its portfolio. The Zacks Consensus Estimate for 2025 FFO per share has been revised upward to $7.22 [21][22][23] - **Urban Edge Properties (UE)**: Concentrates on retail properties in urban communities, with grocery tenants accounting for about 80% of its portfolio's value. The Zacks Consensus Estimate for its 2025 FFO per share has been raised to $1.42, indicating a 5.2% year-over-year increase [26][28][29]

Core Insights - Akari Therapeutics is presenting new data on its novel antibody drug conjugate (ADC) payload, PH1, at the 40th Annual SITC Meeting, highlighting its immune mechanism-of-action and potential in oncology treatment [1][2]. Company Overview - Akari Therapeutics is focused on developing next-generation spliceosome payload ADCs, with its lead candidate, AKTX-101, targeting the Trop2 receptor on cancer cells [5]. - The PH1 payload is a spliceosome modulator designed to disrupt RNA splicing in cancer cells, showing preclinical efficacy in inducing cancer cell death and activating immune responses [5]. Research Findings - The abstract presented at SITC indicates that the PH1 ADC, in combination with anti-PD-1, resulted in a higher rate of complete tumor regressions compared to a first-in-class ADC with a microtubule inhibitor payload [2]. - The immune response stimulated by the PH1 ADC involves neoantigen activation, antigen-presenting cells, and T-cell activation, leading to enhanced therapeutic potential [2]. Presentation Details - The oral and poster presentations will provide further insights into the findings, with specific sessions scheduled for November 7 and November 9, 2025 [3][4].

Group 1 - The company has released its latest top investment picks for November 2025, emphasizing the timeliness of joining to access these opportunities [1] - The company invests significant resources, over $100,000 annually, into researching profitable investment opportunities, aiming to provide real estate strategies at a lower cost [1] - The approach has garnered over 500 five-star reviews from satisfied members, indicating a positive reception and effectiveness of the investment strategies [2] Group 2 - The company encourages potential members to join now to start maximizing their returns, highlighting the urgency and potential benefits of membership [2]

Core Insights - ADC Therapeutics SA is a global leader in antibody drug conjugates (ADCs) and will host a conference call on November 10, 2025, to report Q3 2025 financial results and operational updates [1][2]. Company Overview - ADC Therapeutics is focused on transforming treatment for patients through its portfolio, including ZYNLONTA (loncastuximab tesirine-lpyl) and an early-stage PSMA-targeting ADC [3]. - The company is headquartered in Lausanne, Switzerland, with operations in London and New Jersey, emphasizing innovation in ADC development from clinical to manufacturing and commercialization [5]. Product Development - ZYNLONTA has received accelerated approval from the FDA and conditional approval from the European Commission for treating relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy [4]. - ADC Therapeutics is also developing a next-generation PSMA-targeting ADC that utilizes a differentiated exatecan-based payload with a novel hydrophilic linker [4].

Core Insights - The article emphasizes the current stock investing landscape, particularly focusing on dividends [1] Summary by Categories Stock Investing Landscape - A comprehensive overview of the stock investing environment is provided, highlighting the significance of dividends in investment strategies [1]

Core Viewpoint - The article discusses two primary methods for generating monthly income through investments, focusing on the advantages of monthly dividend-paying stocks like Realty Income and Agree Realty over quarterly dividend payers [1]. Group 1: Monthly Income Generation - Investors can either buy multiple quarterly dividend stocks to create a monthly income stream or opt for investments that pay monthly dividends [1][3]. - Managing three different quarterly dividend stocks can be complex, requiring careful tracking to ensure a steady income stream [3][4]. Group 2: Monthly Dividend Stocks - Monthly paying dividend stocks are less common, necessitating careful selection to ensure they are sound investments [4]. - AGNC Investment, while offering a high yield of 14%, has a declining dividend history and stock price, highlighting the importance of understanding the underlying investment [5][7]. Group 3: Realty Income and Agree Realty - Realty Income and Agree Realty are traditional property-owning REITs that utilize a net-lease approach, minimizing operational costs for tenants [8]. - Realty Income has a portfolio of over 15,600 properties, while Agree Realty has around 2,600 properties, making Realty Income the larger player in the market [9]. Group 4: Financial Metrics - Realty Income offers a dividend yield of 5.4%, while Agree Realty has a yield of 4.2%, both significantly higher than the S&P 500's yield of approximately 1.2% [11]. - Realty Income has increased its dividend annually for 30 years, whereas Agree Realty has a 10-year streak with a shift to monthly payments in 2021 [11]. Group 5: Growth Potential - Realty Income's dividend has grown by about 30% over the past decade, while Agree Realty's dividend has increased by 60% during the same period, indicating a stronger growth trajectory for Agree [13]. - Given its smaller portfolio, Agree Realty may find it easier to sustain higher growth rates compared to Realty Income [13]. Group 6: Investment Strategy - Realty Income and Agree Realty are considered reliable income stocks that can serve as foundational investments, with the potential for adding more aggressive income options [14].

Core Insights - Companies with a strong history of dividend payments and increases are attractive to income-focused investors, with Black Hills, Genuine Parts, and Agree Realty recently announcing dividend hikes [1] Group 1: Black Hills - Black Hills Corp. operates as an electric and natural gas utility company in the U.S. [2] - The company has increased its dividends for 55 consecutive years, with the most recent hike on January 24, raising the quarterly payout from $0.65 to $0.676 per share, resulting in an annual figure of $2.70 per share [3] - As of June 30, Black Hills reported annual revenue of $2.24 billion, with Q2 2025 revenues of $439 million, which was below the consensus estimate of $448.40 million, while EPS of $0.38 exceeded the consensus of $0.37 [4] Group 2: Genuine Parts - Genuine Parts Co. is a global service provider of automotive and industrial replacement parts [4] - The company has raised its dividends for 69 consecutive years, with the latest increase on February 18, raising the quarterly payout by 3% to $1.03 per share, equating to an annual figure of $4.12 per share [5] - As of September 30, Genuine Parts reported annual revenue of $24.06 billion, with Q3 2025 revenues of $6.26 billion, surpassing the consensus estimate of $6.13 billion, while EPS of $1.98 fell short of the consensus of $2 [6] Group 3: Agree Realty - Agree Realty Corp. is a real estate investment trust that focuses on acquiring and developing properties net leased to leading omnichannel retail tenants [7]

Core Insights - The article emphasizes the benefits of investing in Real Estate Investment Trusts (REITs) for generating passive income, particularly for dividend-focused investors [1]. Group 1: Investment Strategy - The investment strategy discussed revolves around a buy-and-hold approach, focusing on quality investments in REITs, blue-chip stocks, and Business Development Companies (BDCs) [2]. - The goal is to supplement retirement income through dividends within a 5-7 year timeframe, targeting lower and middle-class workers to build high-quality investment portfolios [2]. Group 2: Analyst's Position - The analyst holds a beneficial long position in ADC shares, indicating a personal investment commitment to the discussed stocks [3]. - The article reflects the analyst's independent opinions and is not influenced by external compensation, ensuring an unbiased perspective [3].